Project Grant R43HG012960

Award Date 8/15/23
Completion Date 7/31/24
Dollars Obligated $391K
Federal Grant Program
93.172
Assistance Type
Project Grant
Place of Performance
West Menlo Park, CA 94025, USA
Similar Awards
This $350,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development and optimization of a novel, enzyme-based, single-molecule protein sequencing system by Electronic Biosciences, Inc. The objective is to create a rapid, reliable, and cost-effective platform that can accurately sequence proteins, including those with post-translational modifications, through the...
The National Human Genome Research Institute (NHGRI), under the Federal Grant Program "Human Genome Research" (CFDA 93.172), awarded a $407,291 Phase I Small Business Innovation Research (SBIR) grant to Electronic Biosciences, Inc. to develop a nanopore-based protein sequencing platform. The project aims to create a high-accuracy, label-free nanopore reader capable of direct, single-molecule protein sequencing. This novel technology would enable proteome-wide profiling, biomarker...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides $306,860 to Mixedlcmedia LLC, a small disadvantaged business, to develop and evaluate a prototype ultra-low flow liquid chromatography platform based on their proprietary porous layer open-tubular (PLOT) and monolithic nanocolumn technologies. The goal is to create a commercialization-ready LC system that enables deep proteomic...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $205,926 to Abbratech Inc., a small disadvantaged biotechnology business located in Branford, CT. The overarching goal of this "Fast Track" research project is to develop a comprehensive platform for identifying and validating recombinant antibodies that target protein isoform splice-junction sites. This addresses key...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), provides $2,297,901 to GMJ Technologies, Inc., a minority-owned small disadvantaged business, to develop a high-resolution native capillary zone electrophoresis system with inline UV and native mass spectrometry capabilities. This innovative analytical technology aims to enhance the characterization and quality control of protein...
The National Institute of General Medical Sciences (NIGMS) awarded a $917,454 Project Grant under CFDA 93.859, Biomedical Research and Research Training, to Integral Molecular Inc. The grant supports the development of a novel Membrane Proteome Array (MPA) technology for specificity screening and profiling of biotherapeutics like monoclonal antibodies and CAR-T cell therapies. The MPA represents 93% of the human extracellular proteome expressed in native conformation, providing a more...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA program 93.859 Biomedical Research and Research Training provides $350,000 to Fluidispec LLC to develop a new microfluidic/nanofluidic sample preparation platform. The goal is to improve single-cell and low-input proteomics analysis by enabling efficient extraction of proteins from cells, removal of contaminants, and improved protein denaturation. This platform is expected to enhance...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is funding the development of a Spotting-Free Nano-Oscillator Array (SFNOA) technology by Biosensing Instrument Inc., a for-profit company based in Tempe, Arizona. The SFNOA platform aims to enable high-throughput, label-free quantification of ligand binding kinetics to transmembrane proteins in their native states. The $349,566 award, with a...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $295,561 to Biosensing Instrument Inc. to develop a commercial prototype of their Plasmonic Scattering Microscopy (PSM) technology. The PSM system aims to enable high-throughput, label-free quantification of membrane protein binding kinetics on single cells in their native cellular microenvironment. This represents a...
This federal Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of novel molecular technologies for targeted protein degradation. Specifically, the $299,978 award to Lifesensors Inc., a biotechnology company in Malvern, PA, will fund research on "molecular glue degraders" - small molecules that can induce proximity between target proteins and E3...

SINGLE-MOLECULE PROTEIN SEQUENCING BY DETECTION AND IDENTIFICATION OF N-TERMINAL AMINO ACIDS - SUMMARY - SUBTLE CHANGES IN PROTEIN EXPRESSION ARE CRITICAL FOR PROPER GROWTH AND DEVELOPMENT, BUT IRREGU- LARITIES CAN CAUSE DELETERIOUS CELLULAR EFFECTS OR LARGE-SCALE BIOLOGICAL DYSFUNCTION. SEQUENCING SAMPLES WITH COMPLEX MIXTURES OF PROTEINS COULD GREATLY ACCELERATE RESEARCH INTO PROTEIN FUNCTION AND BIOLOGY, BUT THERE IS CURRENTLY NO EFFICIENT AND COST-EFFECTIVE STRATEGY FOR PROTEIN SEQUENCING AT SINGLE-AMINO-ACID RESOLUTION. TWO METHODS ARE COMMERCIALLY AVAILABLE FOR PROTEIN SEQUENCING. IN THE FIRST, "EDMAN DEGRADATION", BULK QUANTI- TIES OF WHOLE PROTEIN OR PURIFIED FRAGMENTS ARE SEQUENCED BY CLEAVING THE FIRST (N-TERMINAL) AMINO ACID AND CHEM- ICALLY IDENTIFYING IT. IN THE SECOND METHOD, BASED ON MASS SPECTROMETRY, A SINGLE PROTEIN OR MIXTURE OF PROTEINS IS FRAGMENTED, AND THE MOLECULAR MASS AND CHARGE OF EACH FRAGMENT ARE ANALYZED. THIS INFORMATION IS COMPARED KNOWN PROTEIN SEQUENCES TO INFER THE IDENTITY OF THE INPUT PROTEINS. BOTH OF THESE METHODS REQUIRE ~1 MILLION MOLECULES OF EACH PROTEIN, AND EDMAN DEGRADATION CANNOT CURRENTLY BE USED ON HETEROGENOUS PROTEIN MIXTURES. EXISTING APPROACHES FOR SINGLE MOLECULE PROTEIN SEQUENCING ARE HINDERED BY THE NUMBER AND DIVERSITY OF AMINO ACIDS, AS WELL AS THE INTERACTIONS BETWEEN AMINO ACIDS THAT INTERFERE WITH CHEMICAL IDENTIFICATION OF THEIR SIDE CHAINS. HARSH DENATURATION AGENTS CAN MITIGATE SOME ISSUES, BUT THEY CAN COMPROMISE THE IDENTIFICATION SYSTEMS THEMSELVES. IN ADDITION, DENATURATION AGENTS ONLY REMOVE SOME OF THE INTRAMOLECULAR INTERACTIONS OF PROTEINS. GLYPHIC BIOTECHNOLOGIES IS DEVELOPING A NOVEL STRATEGY TO SEQUENCE INDIVIDUAL PROTEIN MOLECULES IN THEIR ENTIRETY FROM A HETEROGENEOUS SAMPLE. THIS PROCESS IS BASED ON LIGATING THE N-TERMINAL AMINO ACID TO A CLEAVABLE CHEM- ICAL LINKER, WHICH SUBSEQUENTLY TETHERS IT LOCALLY TO THE SURFACE. CLEAVAGE OF THE LINKER REMOVES THE N-TERMINAL AMINO ACID FROM THE PROTEIN FOR HIGHLY SENSITIVE IDENTIFICATION WITH NO INTERFERENCE FROM PROTEIN STRUCTURE OR ADJA- CENT AMINO ACIDS. THE PROCESS IS REPEATED FOR EACH SUBSEQUENT AMINO ACID, YIELDING THE PROTEIN SEQUENCE. THE APPROACH MAY SIMULTANEOUSLY SEQUENCE MILLIONS TO BILLIONS OF INDIVIDUAL PROTEIN MOLECULES IN HOURS, WHICH WILL REVOLUTIONIZE PROTEIN ANALYSIS BY MAKING LARGE-SCALE PROTEIN SEQUENCING FEASIBLE, INEXPENSIVE, AND ROUTINE. THE CURRENT PROPOSAL FOCUSES ON DEVELOPING REAGENTS SPECIFICALLY TO DETECT THE N-TERMINAL AMINO ACID OF PROTEINS, ALLOWING AMINO ACIDS TO BE DIGITALLY IDENTIFIED VIA THIS N-TERMINAL ISOLATION STRATEGY. IN AIM 1 WE WILL GENERATE ANTIBODIES TO RECOGNIZE AT LEAST 10 DIFFERENT ISOLATED AMINO ACIDS - ENOUGH TO IDENTIFY ~90% OF THE PROTEOME AFTER 10 SEQUENCING ROUNDS. IN AIM 2 WE WILL FURTHER OPTIMIZE THE ANTIBODIES AND DEMONSTRATE THE FEASIBILITY OF USING THEM TO SEQUENCE INDIVIDUAL PROTEINS AMONG A BACKGROUND OF NON-MODIFIED PROTEINS. SUCCESS OF THESE AIMS WILL ENABLE THE GLYPHIC PROTEIN SEQUENCING PLATFORM TO DETECT, QUANTIFY, AND SEQUENCE SINGLE PROTEINS IN COMPLEX PROTEIN MIXTURES IN AN UNBIASED FASHION - WITHOUT ANY PRIOR KNOWLEDGE OF THEIR IDENTITY OR EVEN THEIR EXISTENCE. WHEN COMMERCIALIZED, IT WILL ENABLE CLINICAL DIAGNOSIS OF DISEASE BASED ON THE PROTEINS PRESENT IN A PATIENT SAMPLE AND ALLOW IDENTIFICATION OF UNIQUE PROTEINS TO FOR AS-YET UNKNOWN BIOMARKERS.

Posted 8/15/23, 12:00 AM